PPBT
Purple Biotech
NASDAQ: PPBT · HEALTHCARE · BIOTECHNOLOGY
$4.23
-6.90% today
Updated 2026-04-29
Market cap
$6.95M
P/E ratio
—
P/S ratio
58.08x
EPS (TTM)
$-54.00
Dividend yield
—
52W range
$4 – $29
Volume
0.0M
Purple Biotech (PPBT) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
-67.2%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
-18179.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+4.6%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+18.1%
2026-03-03
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-03 | $-49.36 | -1351.6% | $4.25 | $5.02 | +18.1% |
| 2025-11-13 | $-0.29 | +88.9% | $0.79 | $0.72 | -9.0% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-3.40 | $-49.36 | -1351.6% | — | — |
| 2025-09-30 | $-2.60 | $-0.29 | +88.9% | — | — |
| 2025-06-30 | $-0.21 | $-0.40 | -90.5% | — | — |
| 2025-03-31 | — | $-0.17 | — | — | — |
| 2024-12-31 | $-0.22 | $-0.27 | -22.7% | — | — |
| 2024-09-30 | $-0.06 | $-1.37 | -2183.3% | — | — |
| 2024-06-30 | $-0.16 | $-0.09 | +45.7% | — | — |
| 2024-03-31 | $-0.19 | $-0.14 | +26.3% | — | — |
| 2023-12-31 | $-0.19 | $-0.20 | -3.2% | — | — |
| 2023-09-30 | $-0.23 | $-0.23 | +0.0% | — | — |
| 2023-06-30 | $-0.30 | $-0.25 | +16.7% | — | — |
| 2023-03-31 | $-0.36 | $-0.25 | +30.6% | — | — |
Frequently asked questions
Has Purple Biotech beaten earnings estimates?
Purple Biotech has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of -67.2% over the last 3 quarters.
How does PPBT stock react to earnings?
PPBT stock has moved an average of +4.6% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.